Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer’s disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered. (Journal of Neuroscience, Sept. 14, 2011.)
“Big pharmaceutical companies have been trying for 100 years to find out how to traverse the blood-brain barrier and still keep patients alive,” said Bynoe, who with colleagues have patented the findings and have started a company, Adenios Inc., which will be involved in drug testing and preclinical trials.
It makes it sound like having a wide-open BBB, such as we may have in CCSVI in MS, is not a safe good thing!
Thanks for the link, Erika. I am not sure how the researchers think this will be useful in MS, since closing the BBB to leukocytes is a goal with disease-modifying drugs.